BioAtla (NASDAQ:BCAB) Stock Price Up 3.7% – Still a Buy?

BioAtla, Inc. (NASDAQ:BCAB)’s stock price traded up 3.7% during trading on Friday . The stock traded as high as $3.80 and last traded at $3.68. Approximately 41,216 shares traded hands during mid-day trading, a decline of 37% from the average daily volume of 65,113 shares. The stock had previously closed at $3.55.

Wall Street Analyst Weigh In

BCAB has been the subject of a number of recent research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of BioAtla in a research note on Wednesday, June 3rd. Wall Street Zen upgraded BioAtla to a “hold” rating in a research note on Saturday, April 11th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, BioAtla presently has a consensus rating of “Hold” and a consensus price target of $200.00.

BioAtla Price Performance

The business’s fifty day simple moving average is $4.06 and its two-hundred day simple moving average is $11.97. The company has a market cap of $6.11 million, a PE ratio of -0.09 and a beta of 0.79.

BioAtla (NASDAQ:BCAB) last posted its earnings results on Friday, May 15th. The company reported ($4.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($10.00) by $5.78.

Institutional Trading of BioAtla

A number of institutional investors and hedge funds have recently made changes to their positions in BCAB. Woodline Partners LP purchased a new position in shares of BioAtla during the 1st quarter valued at approximately $26,000. ADAR1 Capital Management LLC acquired a new stake in shares of BioAtla in the fourth quarter valued at about $104,000. Susquehanna International Group LLP grew its position in shares of BioAtla by 237.6% in the third quarter. Susquehanna International Group LLP now owns 252,583 shares of the company’s stock valued at $174,000 after purchasing an additional 177,760 shares during the period. Millennium Management LLC purchased a new stake in shares of BioAtla during the third quarter worth about $235,000. Finally, Jane Street Group LLC increased its stake in shares of BioAtla by 55.4% during the fourth quarter. Jane Street Group LLC now owns 346,774 shares of the company’s stock worth $197,000 after purchasing an additional 123,597 shares in the last quarter. 77.23% of the stock is currently owned by hedge funds and other institutional investors.

BioAtla Company Profile

BioAtla, Inc (NASDAQ: BCAB) is a clinical?stage biotechnology company focused on the development of conditionally active biologics (CABs) for oncology and other serious diseases. Utilizing its proprietary CAB technology platform, BioAtla engineers monoclonal antibodies, bispecifics and antibody-drug conjugates that remain inactive in healthy tissues but become activated in the tumor microenvironment. This targeted approach aims to improve therapeutic index by enhancing anti?tumor potency while minimizing off-target effects and systemic toxicity.

Founded in 2012 and headquartered in San Diego, California, BioAtla has advanced multiple product candidates into clinical trials.